AFT Pharmaceuticals (NZSE:AFT) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

AFT Overzicht aandelen

AFT Pharmaceuticals Limited houdt zich samen met haar dochterondernemingen bezig met de ontwikkeling en verkoop van farmaceutische producten in Nieuw-Zeeland, Australië, Azië en internationaal.

Over het bedrijf

AFT fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	3/6
Prestaties in het verleden	5/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 79.5% onder onze schatting van de reële waarde

De winst zal naar verwachting met 18.07% per jaar groeien

De winst groeide het afgelopen jaar met 46.5%

Risicoanalyse

Geen risico's gedetecteerd voor AFT uit onze risicocontroles.

AFT Pharmaceuticals Limited Concurrenten

BLIS Technologies

NZSE:BLT

NZ$16.6m

Sigachi Industries

NSEI:SIGACHI

₹17.7b

GlaxoSmithKline Pakistan

KASE:GLAXO

PK₨62.7b

Daewon Pharmaceutical

KOSE:A003220

₩310.4b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor AFT Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	NZ$3.05
52 Week Hoogtepunt	NZ$3.85
52 Week Laag	NZ$2.60
Bèta	0.37
11 maand verandering	-9.76%
3 maanden verandering	4.10%
1 Jaar Verandering	-7.01%
33 jaar verandering	-24.13%
5 jaar verandering	0%
Verandering sinds IPO	-1.61%

Recent nieuws en updates

It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

Jul 26

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

May 25

Recent updates

It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

Jul 26

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

May 25

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

Jul 30

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Jun 02

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

Mar 20

A Quick Analysis On AFT Pharmaceuticals' (NZSE:AFT) CEO Compensation

Feb 13

Are AFT Pharmaceuticals's (NZSE:AFT) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Jan 23

Does AFT Pharmaceuticals (NZSE:AFT) Have A Healthy Balance Sheet?

Jan 02

Should AFT Pharmaceuticals (NZSE:AFT) Be Disappointed With Their 89% Profit?

Dec 12

AFT Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Nov 21

Rendement voor aandeelhouders

	AFT	NZ Pharmaceuticals	NZ Markt
7D	-3.5%	-6.2%	0.7%
1Y	-7.0%	73.2%	6.9%

Rendement versus industrie: AFT presteerde slechter dan de NZ Pharmaceuticals -sector, die het afgelopen jaar een rendement van 87.9 % opleverde.

Rendement versus markt: AFT presteerde slechter dan NZ Market, dat het afgelopen jaar een rendement van 6.2 % opleverde.

Prijsvolatiliteit

Is AFT's price volatile compared to industry and market?
AFT volatility
AFT Average Weekly Movement	4.6%
Pharmaceuticals Industry Average Movement	10.5%
Market Average Movement	4.6%
10% most volatile stocks in NZ Market	10.2%
10% least volatile stocks in NZ Market	3.2%

Stabiele aandelenkoers: AFT heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van AFT is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1997	110	Hartley Atkinson	www.aftpharm.com

AFT Pharmaceuticals Limited houdt zich, samen met haar dochterondernemingen, bezig met de ontwikkeling en verkoop van farmaceutische producten in Nieuw-Zeeland, Australië, Azië en internationaal. Het biedt producten aan voor gebruik op het gebied van allergie, gastro-intestinaal, verkoudheid en griep, spijsvertering, oogverzorging, eerste hulp, nagelverzorging, mondverzorging, pijnbestrijding, huidverzorging, vitaminen en supplementen, evenals andere producten. AFT Pharmaceuticals Limited werd opgericht in 1997 en het hoofdkantoor is gevestigd in Auckland, Nieuw-Zeeland.

AFT Pharmaceuticals Limited Samenvatting

Hoe verhouden de winst en inkomsten van AFT Pharmaceuticals zich tot de beurswaarde?
AFT fundamentele statistieken
Marktkapitalisatie	NZ$319.84m
Inkomsten(TTM)	NZ$15.61m
Inkomsten(TTM)	NZ$195.41m

20.5x

Koers/Winstverhouding

1.6x

P/S-verhouding

Is AFT overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
AFT resultatenrekening (TTM)
Inkomsten	NZ$195.41m
Kosten van inkomsten	NZ$107.14m
Brutowinst	NZ$88.27m
Overige uitgaven	NZ$72.66m
Inkomsten	NZ$15.61m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.15
Brutomarge	45.17%
Nettowinstmarge	7.99%
Schuld/Eigen Vermogen Verhouding	32.1%

Hoe presteerde AFT op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.5%

Huidig dividendrendement

11%

Uitbetalingsratio

AFT Overzicht aandelen

Beloningen

Risicoanalyse

AFT Pharmaceuticals Limited Concurrenten

NZSE:BLT

NZ$16.6m

NSEI:SIGACHI

₹17.7b

KASE:GLAXO

PK₨62.7b

KOSE:A003220

₩310.4b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Price target increased by 24% to NZ$4.60

It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

Upcoming dividend of NZ$0.016 per share

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 02, 2024

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Dividend of NZ$0.016 announced

Recent updates

Price target increased by 24% to NZ$4.60

It's Unlikely That The CEO Of AFT Pharmaceuticals Limited (NZSE:AFT) Will See A Huge Pay Rise This Year

Upcoming dividend of NZ$0.016 per share

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 02, 2024

AFT Pharmaceuticals Limited (NZSE:AFT) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Dividend of NZ$0.016 announced

Full year 2024 earnings released: EPS: NZ$0.15 (vs NZ$0.10 in FY 2023)

AFT Pharmaceuticals Limited to Report Fiscal Year 2024 Results on May 23, 2024

Price target decreased by 22% to NZ$3.70

Consensus EPS estimates fall by 12%, revenue upgraded

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited Reaffirms Earnings Guidance for the Fiscal Year 2024

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited to Report First Half, 2024 Results on Nov 23, 2023

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Announces Board Changes

Independent Non-Executive Director recently sold NZ$109k worth of stock

Now 20% undervalued after recent price drop

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 04, 2023

Consensus EPS estimates fall by 17%

Does AFT Pharmaceuticals (NZSE:AFT) Deserve A Spot On Your Watchlist?

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year Ending March 2024

AFT Pharmaceuticals Limited to Report Fiscal Year 2023 Results on May 22, 2023

Price target decreased to NZ$4.22

Consensus forecasts updated

First half 2023 earnings released: EPS: NZ$0.01 (vs NZ$0.04 in 1H 2022)

Is Now The Time To Put AFT Pharmaceuticals (NZSE:AFT) On Your Watchlist?

Price target decreased to NZ$5.51

AFT Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 24, 2022

AFT Pharmaceuticals Limited Update on Maxigesic IV Us Registration Filing

AFT Pharmaceuticals Limited Completes Pascomer Clinical Study

Dr. Doug Wilson to Step Down from AFT Pharmaceuticals Board

US FDA Seeks More Information on AFT Pharmaceuticals Limited's Maxigesic IV Application

Price target decreased to NZ$4.40

AFT Pharmaceuticals Limited, Annual General Meeting, Aug 05, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Should You Be Adding AFT Pharmaceuticals (NZSE:AFT) To Your Watchlist Today?

Investor sentiment improved over the past week

AFT Pharmaceuticals Limited Provides Earnings Guidance for the Year to 31 March 2023

AFT Pharmaceuticals Limited to Report Fiscal Year 2022 Results on May 23, 2022

Price target increased to NZ$5.88

AFT Pharmaceuticals Announces US Food and Drug Administration Approve Topical Treatment Indicated for Facial Angiofibroma

Independent Director recently bought NZ$66k worth of stock

Independent Director recently bought NZ$171k worth of stock

AFT Pharmaceuticals Limited Welcomes Australian Federal Court Appeal Success

Is AFT Pharmaceuticals Limited (NZSE:AFT) Trading At A 50% Discount?

First half 2022 earnings released: EPS NZ$0.04 (vs NZ$0.01 in 1H 2021)

Price target increased to NZ$5.88

We Discuss Whether AFT Pharmaceuticals Limited's (NZSE:AFT) CEO Is Due For A Pay Rise

AFT Pharmaceuticals Got First Regulatory Approval of Maxigesic Oral Liquid in Europe

With AFT Pharmaceuticals Limited (NZSE:AFT) It Looks Like You'll Get What You Pay For

Full year 2021 earnings released

AFT Pharmaceuticals Limited Announces Earnings Guidance for the Fiscal Year 2022

CFO & Company Secretary exercised options to buy NZ$205k worth of stock.

Consensus EPS estimates fall to NZ$0.092

Price target decreased to NZ$4.95

AFT Pharmaceuticals Revises Earnings Guidance for the Year to 31 March 2021

Should You Be Impressed By AFT Pharmaceuticals Limited's (NZSE:AFT) ROE?

AFT Pharmaceuticals Signs an Exclusive Maxigesic IV Licensing Agreement for Eight New European Markets